Remove 2018 Remove PET Scan Remove Radiation
article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.

article thumbnail

GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

Imaging Technology

Additionally, Omni Legend offers a streamlined, simple solution that helps enable technologists to increase efficiency, enhance patient care, and reduce potential radiation exposure to medical staff vii.” iii] Based on orders data of GE HealthCare PET/CT systems since 2010. [iv] Measurement follows NEMA NU 2-2018. [v]

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.

article thumbnail

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

Results demonstrated high detection rates (% positive PET scans) even at low PSA levels. Food and Drug Administration approval for its radiohybrid PET diagnostic imaging product for use in prostate cancer in 2023. In clinical trials , the safety of POSLUMA was evaluated in 747 patients with initial or recurrent prostate cancer.

article thumbnail

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Imaging Technology

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group.